Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hürthle cell) tumours of the thyroid

British Journal of Cancer

Volumn 92, Issue 10, 2005, Pages 1892-1898

  Maximo V ^a   Botelho, T ^a   Capela, J ^b   Soares, P ^a,c   Lima, J ^a   Taveira, A ^a,b   Amaro, T ^d   Barbosa, A P ^d   Preto, A ^a   Harach, H R ^e   Williams, D ^f   Sobrinho Simoes M ^a,b,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c Porto Medical School   (Portugal)

^d PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^e Hospital Dr Arturo Oñativia   (Argentina)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Familial thyroid carcinoma; GRIM 19; H rthle cell tumours; Mitochondrial proteins; Thyroid cancer

Indexed keywords

DNA; RNA; APOPTOSIS REGULATORY PROTEIN; B RAF KINASE; BRAF PROTEIN, HUMAN; GRIM19 PROTEIN, HUMAN; OXIDOREDUCTASE; PROTEIN SUBUNIT;

ADULT; ARTICLE; CANCER SUSCEPTIBILITY; CELL DEATH; CHROMOSOME 19P; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL CANCER; GENE; GENE MUTATION; GENETIC PREDISPOSITION; GRIM 19 GENE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MITOCHONDRION; ONCOCYTOMA; PRIORITY JOURNAL; SOMATIC MUTATION; THYROID PARAFOLLICULAR CELL; THYROID TUMOR; APOPTOSIS; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY;

ADENOMA, OXYPHILIC; ADULT; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; GERM-LINE MUTATION; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; MITOCHONDRIA; MOLECULAR SEQUENCE DATA; NADH, NADPH OXIDOREDUCTASES; PROTEIN SUBUNITS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 20344366798     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602547     Document Type: Article

References (44)

1. Angell JE, Lindner DJ, Shapiro PS, Hofmann ER, Kalvakolanu DV (2000) Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem 275: 33416-33426
2. Attardi G, Yoneda M, Chomyn A (1995) Complementation and segregation behavior of disease-causing mitochondrial DNA mutations in cellular model systems. Biochim Biophys Acta 1271: 241-248
3. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell Jr JE (1999) Stat3 as an oncogene. Cell 98: 295-303
4. Caldenhoven E, van Dijk TB, Solari R, Armstrong J, Raaijmakers JA, Lammers JW, Koenderman L, de Groot RP (1996) STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J Biol Chem 271: 13221-13227
5. Cantwell CA, Sterneck E, Johnson PF (1998) Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1. Mol Cell Biol 18: 2108-2117
6. Canzian F, Amati P, Harach HR, Kraimps JL, Lesueur F, Barbier J, Levillain P, Romeo G, Bonneau D (1998) A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 63: 1743-1748
7. Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL (2000) Molecular basis of Hürthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85: 878-882
8. Chiappetta G, Toti P, Cetta F, Giuliano A, Pentimalli F, Amendola I, Lazzi S, Monaco M, Mazzuchelli L, Tosi P, Santoro M, Fusco A (2002) The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hürthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab 87: 364-369
9. Chidambaram NV, Angell JE, Ling W, Hofmann ER, Kalvakolanu DV (2000) Chromosomal localization of human GRIM-19, a novel IFN-beta and retinoic acid-activated regulator of cell death. J Interferon Cytokine Res 20: 661-665
10. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY (1996) Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272: 719-722
11. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D (2003) BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95: 625-627
12. Darnell Jr JE, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421
13. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954
14. DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press
15. Farrand K, Delahunt B, Wang XL, McIver B, Hay ID, Goellner JR, Eberhardt NL, Grebe SK (2002) High resolution loss of heterozygosity mapping of 17p13 in thyroid cancer: Hurthle cell carcinomas exhibit a small 411-kilobase common region of allelic imbalance, probably containing a novel tumor suppressor gene. J Clin Endocrinol Metab 87: 4715-4721
16. Fearnley IM, Carroll J, Shannon RJ, Runswick MJ, Walker JE, Hirst J (2001) GRIM-19, a cell death regulatory gene product, is a subunit of bovine mitochondrial NADH:ubiquinone oxidoreductase (complex I). J Biol Chem 276:38345-38348
17. Finn SP, Smyth P, O'Leary J, Sweeney EC, Shells O (2003) Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma. J Clin Endocrinol Metab 88: 938-941
18. Fukada T, Ohtani T, Yoshida Y, Shirogane T, Nishida K, Nakajima K, Hibi M, Hirano T (1998) STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J 17: 6670-6677
19. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD (2000) Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 97: 4227-4232
20. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Delia Porta G, Fusco A, Vecchio G (1990) PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60: 557-563
21. Hamperl H (1962) Benign and malignant oncocytoma. Cancer 15: 1019-1027
22. Hofmann ER, Boyanapalli M, Lindner DJ, Weihua X, Hassel BA, Jagus R, Gutierrez PL, Kalvakolanu DV, Hofman ER (1998) Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid. Mol Cell Biol 18: 6493-6504
23. Huang G, Lu H, Hao A, Ng DC, Ponniah S, Guo K, Lufei C, Zeng Q, Cao X (2004) GRIM-19, a cell death regulatory protein, is essential for assembly and function of mitochondrial complex I. Mol Cell Biol 24: 8447-8456
24. Hwang JH, Kim DW, Suh JM, Kim H, Song JH, Hwang ES, Park KC, Chung HK, Kim JM, Lee TH, Yu DY, Shong M (2003) Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation. Mol Endocrinol 17: 1155-1166
25. Katoh R, Harach HR, Williams ED (1998) Solitary, multiple, and familial oxyphil tumours of the thyroid gland. J Pathol 186: 292-299
26. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457
27. Li LY, Luo X, Wang X (2001) Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412: 95-99
28. Liu X, Kim CN, Yang J, Jemmerson R, Wang X (1996) Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86: 147-157
29. Lufei C, Ma J, Huang G, Zhang T, Novotny-Diermayr V, Ong CT, Cao X (2003) GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. EMBO J 22: 1325-1335
30. Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simões M (2002) Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol 160: 1857-1865
31. Maximo V, Sobrinho-Simões M (2000a) Hurthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch 437: 107-115
32. Maximo V, Sobrinho-Simões M (2000b) Mitochondrial DNA 'common' deletion in Hurthle cell lesions of the thyroid. J Pathol 192: 561-562
33. Nesland JM, Sobrinho-Simões M, Holm R, Sambade MC, Johannessen JV (1985) Hurthle-cell lesions of the thyroid: a combined study using transmission electron microscopy, scanning electron microscopy, and immunocytochemistry. Ultrastruct Pathol 8: 269-290
34. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008
35. Rosai J, Carcangiu ML, DeLellis RA (1992) Tumours of the thyroid gland. In Atlas of Tumour Pathology 3rd series, Armed Forces Institute of Pathology (ed). Washington: Armed Forces Institute of Pathology
36. Soares P, Fonseca E, Wynford-Thomas D, Sobrinho-Simões M (1998) Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? J Pathol 185: 71-78
37. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Máximo V, Botelho T, Seruca R, Sobrinho-Simões M (2003) BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22: 4578-4580
38. Sobrinho-Simões M (1995) Tumours of thyroid: a brief overview with emphasis on the most controversial issues. Curr Diag Pathol 2: 15-22
39. Sobrinho-Simões M, Nesland JM, Holm R, Sambade MC, Johannessen JV (1985) Hurthle-cell lesions of the thyroid: a combined study using transmission electron microscopy, scanning electron microscopy, and immunocytochemistry. Ultrastruct Pathol 8: 131-142
40. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL (1998) Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 83: 4116-4122
41. Tallini G, Ladanyi M, Rosai J, Jhanwar SC (1994) Analysis of nuclear and mitochondrial DNA alterations in thyroid and renal oncocytic tumors. Cytogenet Cell Genet 66: 253-259
42. Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, Abrosimov A, Guiu XM, Sobrinho-Simoes M (2004) BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 202: 247-251
43. Yeh JJ, Lunetta KL, van Orsouw NJ, Moore Jr FD, Mutter GL, Vijg J, Dahia PL, Eng C (2000) Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene 19: 2060-2066
44. Zhang J, Yang J, Roy SK, Tininini S, Hu J, Bromberg JF, Poli V, Stark GR, Kalvakolanu DV (2003) The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci USA 100: 9342-9347